Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

American Capital Ltd. (ACAS): 1 Company Facing an Uphill Battle

Page 1 of 2

Source: Valerie Everett, Flickr.

Earlier this week, I applauded American Capital Ltd. (NASDAQ:ACAS)‘s asset management subsidiary as a rock star.

As the manager of American Capital Agency Corp. (NASDAQ:AGNC) and American Capital Mortgage Investment Crp (NASDAQ:MTGE), American Capital can reward itself with more than $100 million in annual dividends.

But the asset management subsidiary only makes up about 19% of net asset value.

What about the other 81%?

Truth be told, the fast-growing asset management business has largely covered up material weakness in other segments of the company.

In the latest quarter, American Capital Ltd. (NASDAQ:ACAS) recorded $130 million in operating revenue, which includes all dividends and interest income. After all operating expenses — interest, salaries, and general and administration expenses — pre-tax operating income comes to $65 million for the quarter.

Removing the effects of a $29 million dividend from its asset management business in the second quarter, pre-tax operating profits came in at just $36 million.

The big problem

Pre-tax operating profits are what drive dividends for business development companies. Generally speaking, BDCs seek to invest in debt and equity that offer routine dividends and interest payments. Those dividends and interest payments are then deployed as a “base” dividend payment that can be supplemented with sporadic special dividends.

Main Street Capital Corporation (NYSE:MAIN) is a BDC that uses this model — it pays out regular dividends that are supplemented with semi-annual dividends from profits from the sale of equity in portfolio companies. Despite the fact that it is one of the lower-yielding BDCs, investors have no qualms paying well over book value for its shares.

Unfortunately, if American Capital Ltd. (NASDAQ:ACAS) were to pay out all of its operating income as a dividend, it would fall seriously short of BDC investors’ expectations.

American Capital Ltd. (NASDAQ:ACAS) reports a book value of $5.58 billion. Removing the asset manager from the mix gives us a book value of $4.6 billion. Thus, American Capital Ltd. (NASDAQ:ACAS) is essentially telling shareholders that its portfolio is worth $4.6 billion even though it generated just $36 million in pre-tax operating profits in the last quarter.

If we take $36 million of pre-tax quarterly operating profits and divide it by book value of $4.6 billion, we get a yield of just 3.1% per year. Including the asset manager, American Capital would be a BDC with book value of $5.58 billion that pays out a dividend of 4.65% annually. That’s better, certainly, but it’s nothing compared to yields of 8%-12% from other BDCs.

Explaining away the discount to NAV

If you’ve followed me this far, you’re probably starting to see why American Capital trades at one of the largest discounts to NAV in the BDC universe: Its net operating income would not create a BDC-like yield. For American Capital’s stock to yield 9%, it would need to trade at just half of NAV. Shares currently trade at a 31% discount to second-quarter NAV.

For American Capital to trade at or near NAV, it must show substantial improvements in net operating income to justify a higher potential dividend and thus a higher stock price. Alternatively, it needs considerable improvements in the value of its portfolio investments, and subsequently large equity exits.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!